论文部分内容阅读
目的探讨阿德福韦对慢性乙型肝炎患者血清白介素(IL)-6、12和18水平的影响及疗效观察。方法选择70例慢性乙型肝炎患者,随机分为观察组和对照组。两组患者均予以门冬氨酸钾镁、还原型谷胱苷肽和复方甘草酸苷等常规保肝治疗。对照组加用干扰素α-2b治疗5 000 000 U,肌注,1次/d,10 d后改为隔日1次,连用6个月。观察组加用阿德福韦酯片10 mg/次,1次/d,连用6个月。观察两组患者治疗前后血清IL-6、IL-12、IL-18水平的变化,并进行抗病毒疗效比较。结果治疗6个月后,两组患者血清IL-6、IL-12、IL-18水平均有明显下降(P<0.01或P<0.05),且观察组比对照组下降的幅度更明显(P<0.05)。治疗6个月后,观察组抗病毒治疗的疗效明显高于对照组(χ2=4.16,P<0.05)。结论阿德福韦治疗慢性乙型肝炎的抗病毒治疗的疗效确切,能抑制细胞因子IL-6、IL-12、IL-18的作用,从而阻止肝纤维化的进展。
Objective To investigate the effects of adefovir on the levels of serum interleukin (IL) -6, 12, and 18 in patients with chronic hepatitis B and its clinical efficacy. Methods Seventy patients with chronic hepatitis B were randomly divided into observation group and control group. Two groups of patients were given conventional aspartate potassium magnesium, reduced glutathione and compound glycyrrhizin and other conventional liver protection. The control group plus interferon α-2b treatment of 5 000 000 U, intramuscular injection, 1 / d, 10 days later changed to every other day, once every 6 months. Observation group plus adefovir dipivoxil 10 mg / time, 1 / d, once every 6 months. The changes of serum IL-6, IL-12 and IL-18 levels before and after treatment in both groups were observed, and the anti-virus efficacy was compared. Results After 6 months treatment, the levels of serum IL-6, IL-12 and IL-18 in both groups were significantly decreased (P <0.01 or P <0.05), and the decrease in the observation group was more significant than that in the control group <0.05). After 6 months of treatment, the efficacy of antiviral therapy in the observation group was significantly higher than that in the control group (χ2 = 4.16, P <0.05). Conclusion Adefovir treatment of chronic hepatitis B antiviral therapy curative effect is exact, can inhibit the cytokines IL-6, IL-12, IL-18 role, thereby preventing the progress of liver fibrosis.